Switchback Medical Is Expanding Into Costa Rica

Why It Matters

By establishing a near‑shoring hub, Switchback can shorten development cycles, lower production costs, and better serve U.S. and regional customers, strengthening its competitive position in the fast‑growing medtech CDMO market.

Key Takeaways

• Switchback leases 18,000‑sq ft facility in Costa Rica’s Coyol FTZ.
• Facility includes 3,500‑sq ft cleanroom for medical device components.
• Second, larger Evolution site slated for 2027, expanding capacity.
• Expansion leverages free‑trade benefits and skilled local workforce.
• Supports early‑stage development to full‑scale production for interventional devices.

Pulse Analysis

The medtech industry is increasingly turning to near‑shoring to mitigate supply‑chain disruptions and reduce tariff exposure. Costa Rica’s Free Trade Zones offer tax incentives, streamlined customs, and a multilingual, technically trained labor pool, making the country an attractive alternative to traditional Asian manufacturing hubs. For contract development and manufacturing organizations, proximity to the U.S. market translates into faster prototype iterations and quicker regulatory feedback, essential for devices that must meet stringent ISO 13485 standards.

Switchback Medical’s Coyol lease underscores a strategic shift toward integrated development‑to‑production services. By embedding a 3,500‑square‑foot cleanroom within the 18,000‑square‑foot campus, the company can handle extrusion, braided shafts, and precision components on‑site, accelerating product transfers for existing clients. The immediate focus on thermoplastic extrusion aligns with rising demand for minimally invasive interventional tools, while the planned Evolution facility will eventually support full device assembly, positioning Switchback as a one‑stop supplier for neurovascular and structural heart manufacturers.

Long‑term, the dual‑site footprint could reshape regional medtech dynamics. As more U.S. device firms seek agile partners, Switchback’s presence may catalyze a cluster effect, attracting ancillary suppliers and fostering innovation ecosystems in Costa Rica. The 2027 Evolution launch promises scalability for high‑volume production, potentially drawing larger OEM contracts away from traditional offshore sites. This expansion not only bolsters Switchback’s revenue pipeline but also signals confidence in Latin America’s capacity to host sophisticated, regulated medical manufacturing operations.